Evrysdi (Risdiplam) Patent Expiration, LOE Window & CMS Spending
Evrysdi (Risdiplam) by Roche / Genentech: FDA Orange Book core substance LOE 2041-04-15, 0 AB generics, $499.8M 2024 CMS Part D & Medicaid spend, and $33,653 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Roche / Genentech |
| FDA Application & Pathway | N213535 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2041-04-15 |
| Last Listed Patent or Exclusivity Date | 2041-04-15 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $499.8M |
| 2024 Medicare Part D Spend | $154.5M |
| 2024 Medicaid Spend | $345.3M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($33,653 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.